Shanghai Celgen Biopharma

Shanghai Celgen Biopharma is a high-tech biopharmaceutical company based in China, specializing in the development, manufacturing, and commercialization of recombinant protein and monoclonal antibody drugs. The company is best known for its flagship product, Qiangke (etanercept), a recombinant human tumor necrosis factor receptor-antibody fusion protein used to treat autoimmune diseases such as rheumatoid arthritis and ankylosing spondylitis. Celgen operates a large-scale mammalian cell culture production base in Shanghai, adhering to international GMP standards. Its pipeline focuses on biosimilars and innovative biologics targeting oncology and inflammatory conditions, aiming to provide affordable, high-quality therapeutic options for the Chinese market.